Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

September 13, 2016

The Cold Truth: Cryopreservation of Final Product in Cell Therapy Manufacturing

While using cell therapies that have a short shelf-life due to a “fresh” final product (meaning the product is not designed for long-term storage) is perfectly ...

June 22, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 3

This is the third in a three-part series (read Part 1 and Part 2 for the complete picture). As you approach cell therapy commercialization—having traveled what is still ...

June 15, 2016

Precious Cargo: Challenges in the Cell Therapy Transportation Supply Chain

The following is a guest blog by Kevin O’Donnell, Vice President, Cold Chain Standards, Practices & Compliance, BioLife Solutions As forecast by the White House 2012 ...

June 8, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 2

This is the second in a three-part series (Part 1 can be found here). As you enter this mid-phase of development, we reflect on these words from Albert Einstein: “In the ...

June 6, 2016

Managing the Challenges of Cell Therapy Product Delivery in Clinical and Commercial Settings

PCT was recently featured in the BioProcess International Industry Yearbook. The article by Sanjin Zvonic, Ph.D., Director of Technology and Business Development for ...

June 2, 2016

Manufacturing – The Existential Crisis for Patient-Specific Cell Therapies

It is no secret that patient-specific cell therapies are widely perceived to be expensive to produce, which leads to expensive products, if they commercialize at all. I ...

May 25, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 1

If you’re reading this, you’ve no doubt already discovered that cell therapy manufacturing comes with its share of specific challenges, no matter what phase of ...

May 18, 2016

Scaling Mountains in Cell Therapy Manufacturing

Growing up, many of us became familiar with the children’s song, ‘The Bear went Over the Mountain’. In this nursery rhyme (of sorts) a bear that succeeds in scaling a ...

May 12, 2016

Reducing Idle Capacity Through the Factory of the Future

The following is an excerpt from an article published in the April issue of BioProcess international, entitled “Factories of the Future: Can Patient-Specific Cell ...

Previous All Posts Next